Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 2
2008 4
2009 5
2010 3
2011 2
2012 6
2013 12
2014 3
2015 8
2016 7
2017 4
2018 7
2019 2
2020 6
2021 3
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG). Eichhorst B, et al. Among authors: maurer c. Lancet Oncol. 2016 Jul;17(7):928-942. doi: 10.1016/S1470-2045(16)30051-1. Epub 2016 May 20. Lancet Oncol. 2016. PMID: 27216274 Clinical Trial.
Breast cancer treatment-induced cardiotoxicity.
Martel S, Maurer C, Lambertini M, Pondé N, De Azambuja E. Martel S, et al. Among authors: maurer c. Expert Opin Drug Saf. 2017 Sep;16(9):1021-1038. doi: 10.1080/14740338.2017.1351541. Epub 2017 Jul 18. Expert Opin Drug Saf. 2017. PMID: 28697311 Review.
[Imported histoplasmosis].
Stete K, Kern WV, Rieg S, Serr A, Maurer C, Tintelnot K, Wagner D. Stete K, et al. Among authors: maurer c. Dtsch Med Wochenschr. 2015 Jun;140(12):913-6. doi: 10.1055/s-0041-102040. Epub 2015 Jun 12. Dtsch Med Wochenschr. 2015. PMID: 26069920 German.
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Buisseret L, Loirat D, Aftimos P, Maurer C, Punie K, Debien V, Kristanto P, Eiger D, Goncalves A, Ghiringhelli F, Taylor D, Clatot F, Van den Mooter T, Ferrero JM, Bonnefoi H, Canon JL, Duhoux FP, Mansi L, Poncin R, Barthélémy P, Isambert N, Denis Z, Catteau X, Salgado R, Agostinetto E, de Azambuja E, Rothé F, Craciun L, Venet D, Romano E, Stagg J, Paesmans M, Larsimont D, Sotiriou C, Ignatiadis M, Piccart-Gebhart M. Buisseret L, et al. Among authors: maurer c. Nat Commun. 2023 Nov 2;14(1):7018. doi: 10.1038/s41467-023-42744-y. Nat Commun. 2023. PMID: 37919269 Free PMC article. Clinical Trial.
New agents for endocrine resistance in breast cancer.
Maurer C, Martel S, Zardavas D, Ignatiadis M. Maurer C, et al. Breast. 2017 Aug;34:1-11. doi: 10.1016/j.breast.2017.04.007. Epub 2017 Apr 24. Breast. 2017. PMID: 28448864 Review.
Male breast cancer: finding the way in this uncommon path.
Maurer C, Martel S, de Azambuja E. Maurer C, et al. ESMO Open. 2017 Mar 16;2(1):e000169. doi: 10.1136/esmoopen-2017-000169. eCollection 2017. ESMO Open. 2017. PMID: 28761736 Free PMC article. No abstract available.
[Folie à deux - Thrombosis and Infections].
Picker J, Schwenke J, Neuenschwander L, Nisslé S, Maurer C, Egli R, Périard D, Staub D, Tsakiris DA, Aujesky D, Tarr P. Picker J, et al. Among authors: maurer c. Praxis (Bern 1994). 2023 Jun;112(7-8):419-425. doi: 10.1024/1661-8157/a004004. Praxis (Bern 1994). 2023. PMID: 37282520 German.
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Martel S, Bruzzone M, Ceppi M, Maurer C, Ponde NF, Ferreira AR, Viglietti G, Del Mastro L, Prady C, de Azambuja E, Lambertini M. Martel S, et al. Among authors: maurer c. Cancer Treat Rev. 2018 Jan;62:123-132. doi: 10.1016/j.ctrv.2017.09.009. Epub 2017 Nov 3. Cancer Treat Rev. 2018. PMID: 29108713 Review.
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.
Agostinetto E, Ameye L, Martel S, Aftimos P, Pondé N, Maurer C, El-Abed S, Wang Y, Vicente M, Chumsri S, Bliss J, Kroep J, Colleoni M, Petrelli F, Del Mastro L, Moreno-Aspitia A, Piccart M, Paesmans M, de Azambuja E, Lambertini M. Agostinetto E, et al. Among authors: maurer c. NPJ Breast Cancer. 2022 Jul 20;8(1):87. doi: 10.1038/s41523-022-00452-8. NPJ Breast Cancer. 2022. PMID: 35859079 Free PMC article.
71 results